{"nctId":"NCT04333420","briefTitle":"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","startDateStruct":{"date":"2020-03-31","type":"ACTUAL"},"conditions":["Severe COVID-19 Pneumonia"],"count":399,"armGroups":[{"label":"Phase II: IFX-1 + BSC","type":"EXPERIMENTAL","interventionNames":["Drug: IFX-1 + BSC"]},{"label":"Phase II: BSC","type":"OTHER","interventionNames":["Drug: BSC"]},{"label":"Phase III: IFX-1 + SOC","type":"EXPERIMENTAL","interventionNames":["Drug: IFX-1 + SOC"]},{"label":"Phase III: Placebo + SOC","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo + SOC"]}],"interventions":[{"name":"IFX-1 + BSC","otherNames":["Vilobelimab + Best Supportive Care"]},{"name":"BSC","otherNames":["Best Supportive Care"]},{"name":"IFX-1 + SOC","otherNames":["Vilobelimab + Standard of Care"]},{"name":"Placebo + SOC","otherNames":["Placebo + Standard of Care"]}],"eligibilityModule":{"eligibilityCriteria":"Phase II\n\nInclusion Criteria:\n\n* At least 18 years of age or older\n* Clinically evident or otherwise confirmed severe pneumonia\n* SARS-CoV-2 infection confirmation (tested positive in last 14 days before randomization with locally available test system)\n\nExclusion Criteria:\n\n* Known history of progressed COPD as evidenced by use of daily maintenance treatment with long-acting bronchodilators or inhaled/oral corticosteroids for \\> 2 months\n* Patient moribund or expected to die in next 24h according to the judgment of the investigator\n* Known severe congestive heart failure (New York Heart Association \\[NYHA\\] Class III- IV)\n* Received organ or bone marrow transplantation in past 3 months\n* Known cardio-pulmonary mechanical resuscitation in past 14 days\n\nPhase III:\n\nInclusion Criteria:\n\n* At least 18 years of age or older\n* Patient on invasive mechanical ventilation (but not more than 48h post intubation at time point of first IMP administration)\n* Patients with a PaO2 / FiO2 ratio of \\< 200 and \\> 60 at randomization (one representative measurement within 6h before randomization)\n* SARS-CoV-2 infection confirmation (tested positive in last 14 days before randomization with locally available test system)\n\nExclusion Criteria:\n\n* Intubated \\> 48 h at time point of first IMP administration\n* Expected stop of invasive ventilation or expected extubation in the next 24h without additional intervention according to judgment of the investigator\n* Known history of chronic dialysis OR received renal replacement therapy in past 14 days OR anticipated to receive renal replacement therapy within 24h after randomization\n* Known history of progressed COPD as evidenced by use of daily maintenance treatment with long-acting bronchodilators or inhaled/oral corticosteroids for \\> 2 months\n* Treatment of COVID-19 with investigational antibody treatment(s) which are not approved or not included in locally adopted treatment guidelines (e.g., WHO guidance, National Institutes of Health \\[NIH\\] COVID-19 treatment guidelines) for this indication in the past 7 days (Note: Antibody treatment\\[s\\] given within past 7 days for pre-existing diseases, other than COVID-19, are allowed.)\n* At time point of randomization, treatment of COVID-19 with investigational treatments which are not approved or not included in locally adopted treatment guidelines for this indication (e.g., WHO guidance, NIH COVID-19 treatment guidelines), including SARS-CoV-2 multiplication inhibitor(s) or immunomodulator(s). (Note: If a locally adopted treatment guideline recommends drugs such as remdesivir, dexamethasone, or anticoagulation, this would be allowed. Adopted guidelines and updates must be documented at study initiation and throughout the conduct of the study.)\n* Received cytokine adsorption therapy in past 3 days\n* Known severe congestive heart failure (corresponding to e.g. NYHA Class III-IV, left ventricular ejection fraction \\<40%)\n* Known history of chronic liver disease (Child-Pugh B or C)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS)","description":"Relative change (%) from baseline in Oxygenation Index (OI; partial pressure of oxygen in the arterial blood (PaO2) / fractional inspired oxygen (FiO2)) in supine position for ≥2 hours at day 5 (FAS)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"31.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Phase III: 28-day All-cause Mortality (FAS)","description":"Number and percentage of deaths (all-cause) until Day 28 (FAS)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"77","spread":null}]},{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"105","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase II: All-cause 28-day Mortality (FAS)","description":"Number and percentage of deaths (all-cause) until Day 28 (FAS)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase II: Early Response at Day 7 After Enrollment","description":"Number of patients (%) achieving an early response at day 7 after enrollment (FAS)","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Phase II: Late Response Until Day 28 After Enrollment","description":"Number of patients (%) reaching a late response until day 28 (FAS)","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position (FAS)","description":"Relative change (%) from baseline in Oxygenation Index (OI) in supine position for ≥2 hours at days 3, 7, 9, 11, and 15 (FAS)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null},{"groupId":"OG001","value":"36.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"82.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase III: 60-day All-cause Mortality (FAS)","description":"Number and percentage of deaths (all-cause) until Day 60 (FAS)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"87","spread":null}]},{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"93","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase III: Percentage of Patients With an Improvement in the 8-point Ordinal Scale (FAS)","description":"Percentage of patients with an improvement in the 8-point ordinal scale (Day 15, Day 28), the scale ranges from 0 = 'No clinical or virological evidence of infection' to 8 = 'Death' with higher scores meaning greater limitation and ventilation/organ support","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"77","spread":null}]},{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"104","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase III: Percentage of Patients Developing Acute Kidney Failure Until Day 28 (FAS)","description":"Percentage of patients developing acute kidney failure (estimated glomerular filtration rate \\[eGFR\\] \\< 15 mL/min/1.73m², assessed by the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation requiring race information) until Day 28 (FAS)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"168","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase III: Percentage of Patients Free of Any Renal Replacement Therapy Within 28 Days Upon Randomization (FAS)","description":"Percentage of patients free of any renal replacement therapy (RRT) within 28 days upon randomization (FAS), number of patients free of any RRT = number of patients - number of patients with RRT initiated after randomization until Day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"161","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":15},"commonTop":["Acute kidney injury","Pneumonia","Pyrexia","Atrial fibrillation","Anaemia"]}}}